Results 31 to 40 of about 21,002 (186)

Tyrosine kinase chromosomal translocations mediate distinct and overlapping gene regulation events

BMC Cancer, 2011
Background Leukemia is a heterogeneous disease commonly associated with recurrent chromosomal translocations that involve tyrosine kinases including BCR-ABL, TEL-PDGFRB and TEL-JAK2. Most studies on the activated tyrosine kinases have focused on proximal
Kim Hani, Gillis Lisa C, Jarvis Jordan D, Yang Stuart, Huang Kai, Der Sandy, Barber Dwayne L   +6 more
doaj   +1 more source

Targeting self-renewal pathways in myeloid malignancies [PDF]

, 2013
A fundamental property of hematopoietic stem cells (HSCs) is the ability to self-renew. This is a complex process involving multiple signal transduction cascades which control the fine balance between self-renewal and differentiation through ...
Copland, M., Sands, W.A., Wheadon, H.
core   +2 more sources

Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia [PDF]

, 2001
Chronic myeloid leukemia (CML) is characterized by formation of the BCR-ABL fusion gene, usually as a consequence of the Philadelphia (Ph) translocation between chromosomes 9 and 22.
Bench, AJ, Campbell, LJ, Grace, C, Green, AR, Huntly, BJP, Nacheva, EP, Prince, HM, Reid, AG, Shepherd, P, Szer, J, Telford, N, Turner, P   +11 more
core   +1 more source

BCR ABL Fusion Protein Detection by a Modern Approach: Fluroscent Immuno Bead Assay

Annals of Oncology, 2012
ABSTRACT Introduction Chronic Myeloid Leukemia (CML) is probably the most extensively studied human malignancy. CML patients (90-95%) harbor the Philadelphia (Ph) chromosome, a shortened chromosome 22, resulting from a reciprocal translocation t (9; 22) (q34; q11) between the long arms of chromosome 9 and 22, fusion ABL proto-oncogene on chromosome ...
S. Dasgupta, U.K. Ray, A. Mukhopadhyay, J. Basak, S. Mukhopadhyay   +4 more
openaire   +1 more source

BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia [PDF]

, 2012
MECOM oncogene expression correlates with chronic myeloid leukaemia (CML) progression. Here we show that the knockdown of MECOM (E) and MECOM (ME) isoforms reduces cell division at low cell density, inhibits colony-forming cells by 34% and moderately ...
Alzuherri, Aytekin, Barjesteh van Waalwijk van Doorn-Khosrovani, Bartholomew, Ben-Neriah, Bianchini, Carapeti, Carlesso, Daghistani, De Weer, Elrick, Fabbro, Fears, Gerhardt, Goyama, Hamilton, Henzan, Hoyt, Huang, Håkansson, Irvine, Jørgensen, Khanna-Gupta, Kilbey, Konopka, Kurzrock, Kustikova, Lin, Livak, Lugthart, Lugthart, Melo, Mitani, Morishita, Morishita, Morishita, Morishita, Nakamura, Nunoda, O'Hare, Ogawa, Paquette, Pendergast, Russell, Sellers, Skorski, Smith, Stevens-Kroef, Suzukawa, Valent, Wetzler, Wieser, Wimmer, Yuasa   +53 more
core   +1 more source

Two different point mutations in ABL gene ATP-binding domain conferring Primary Imatinib resistance in a Chronic Myeloid Leukemia (CML) patient: A case report

Biological Procedures Online, 2004
Imatinib (Gleevec) is the effective therapy for BCR-ABL positive CML patients. Point mutations have been detected in ATP-binding domain of ABL gene which disturbs the binding of Gleevec to this target leading to resistance.
Iqbal Zafar, Siddiqui Rubina T., Qureshi Javed A.   +2 more
doaj   +1 more source

MTSS1 is a critical epigenetically regulated tumor suppressor in CML [PDF]

, 2015
Chronic myeloid leukemia (CML) is driven by malignant stem cells that can persist despite therapy. We have identified Metastasis suppressor 1 (Mtss1/MIM) to be downregulated in hematopoietic stem and progenitor cells from leukemic transgenic SCLtTA/Bcr ...
Braunschweig, T., Brümmendorf, T. H., Chatain, N., Copland, M., Costa, I. G., Gusmao, E. G., Haenzelmann, S., Hamilton, A., Helgason, G.V., Herrmann, O., Holyoake, T. L., Kintsler, S., Koschmieder, S., Li, S., Merle Reher, M., Müller-Tidow, C., Schemionek, M., Schubert, C., Schwab, A.   +18 more
core   +1 more source

Management of imatinib-resistant CML patients [PDF]

, 2007
Imatinib has had marked impact on outcomes in chronic myelogenous leukemia (CML) patients for all stages of the disease and is endorsed by international treatment guidelines as the first line option.
Branford S, Burger H, Burgess MR, Cortes J, Crossman LC, Donato NJ, Druker BJ, Gambacorti-Passerini C, Giles F, Hochhaus A, Hughes TP, Iacobucci I, Kantarjian H, Lahaye T, Mahon FX, Melo JV, O'Hare T, Quintas-Cardama A, Rousselot P, Sleijfer S, Soverini S, Weisberg E   +21 more
core   +1 more source

Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein [PDF]

Blood, 2001
Abstract The BCR-ABL oncogene is central in the pathogenesis of chronic myeloid leukemia (CML). Here, tandem nanospray mass spectrometry was used to demonstrate cell surface HLA-associated expression of the BCR-ABL peptide KQSSKALQR on class I-negative CML cells transfected with HLA-A*0301, and on primary CML cells from HLA-A3–positive ...
Clark, RE, Dodi, IA, Hill, SC, Lill, JR, Aubert, G, Macintyre, AR, Rojas, J, Bourdon, A, Bonner, PLR, Wang, LH, Christmas, SE, Travers, PJ, Creaser, CS, Rees, RC, Madrigal, JA   +14 more
openaire   +3 more sources

Flow Cytometric Immunobead Assay for Detection of BCR-ABL1 Fusion Proteins in Chronic Myleoid Leukemia: Comparison with FISH and PCR Techniques.

PLoS ONE, 2015
Chronic Myeloid Leukemia (CML) is characterized by a balanced translocation juxtaposing the Abelson (ABL) and breakpoint cluster region (BCR) genes.
Anna Grazia Recchia, Nadia Caruso, Sabrina Bossio, Mariavaleria Pellicanò, Laura De Stefano, Stefania Franzese, Angela Palummo, Vincenzo Abbadessa, Eugenio Lucia, Massimo Gentile, Ernesto Vigna, Clementina Caracciolo, Antolino Agostino, Sara Galimberti, Luciano Levato, Fabio Stagno, Stefano Molica, Bruno Martino, Paolo Vigneri, Francesco Di Raimondo, Fortunato Morabito   +20 more
doaj   +1 more source